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Effects of Amlodipine and Lisinopril on Left Ventricular Mass and Diastolic
Function in Previously Untreated Patients with Mild to Moderate Diastolic
Hypertension
FRANK W. BELTMAN1, WILFRED F. HEESEN2, ANDRIES J. SMIT3,5, JOHAN F. MAY2,5, PIETER A. DE
GRAEFF4,5, TJEERD K. HAVINGA5, FRITS H. SCHUURMAN5, ENNO VAN DER VEUR5, KONG I. LIE2 AND
BETTY MEYBOOM-DE JONG1
Departments of General Practice1, Cardiology2, Internal Medicine3, Clinical Pharmacology4, University of Groningen and Groningen
Hypertension Service5, Groningen, The Netherlands
Beltman FW, Heesen WF, Smit AJ, May JF, de Graeff PA, Havinga TK, Schuurman FH, van der
Veur E, Lie KI, Meyboom-de Jong B. Effects of amlodipine and lisinopril on left ventricular mass and
diastolic function in previously untreated patients with mild to moderate diastolic hypertension. Blood
Pressure 1998; 7: 109–117.
The aim of the study was to compare the effects of two long-acting antihypertensive agents, the calcium-
antagonist amlodipine and the ACE inhibitor lisinopril, on left ventricular mass and diastolic filling in
patients with mild to moderate diastolic hypertension from primary care centres. It is a 1-year prospective,
double-blind, randomized, parallel group, comparative study. Patients between 25 and 75 years of age
with untreated hypertension with elevated diastolic blood pressure ( 95 mmHg) on three occasions
(twice on the first visit and once only on the second and third visits) were recruited from a population
survey. After 4 weeks placebo run-in 71 patients were randomized to dosages of amlodipine 5–10 mg or
lisinopril 10–20 mg, which were titrated on the basis of the effects on blood pressure. Fifty-nine patients
completed the study period. Primary endpoints were left ventricular mass index and early to atrial peak
filling velocity. Office and ambulatory blood pressure and other echocardiographic measurements were
considered secondary. Decrease in blood pressure was equal for both treatment regimens. A statistically
significant decrease in left ventricular mass index in both treatment groups was observed: ÿ11.0 g/m2
(95% CI: ÿ6.0, ÿ16.1) in the amlodipine group and ÿ12.6 g/m2 (95% CI: ÿ8.2, ÿ17.0) in the lisinopril
group. The higher the baseline value of left ventricular mass before treatment, the more the decrease after
treatment. Early to atrial peak filling velocity did not change significantly within the treatment groups:
0.07 (95% CI: ÿ0.01, 0.15) in the amlodipine group and 0.01 (95% CI: ÿ0.06, 0.08) in the
lisinopril group. However, analysis of time measurements of the early peak showed significant changes
for both treatment groups. No significant differences in primary and secondary endpoints between
treatment groups were found. Twelve patients did not complete the study, seven in amlodipine and five in
lisinopril, basically due to adverse events. The effects of amlodipine and lisinopril on left ventricular mass
and early to atrial filling peak velocity after 1 year of treatment in patients with previously untreated mild
to moderate hypertension are similar. Further studies are recommended, particularly with a larger sample
size and a follow-up of longer duration. Key words: angiotensin-converting enzyme inhibitor, calcium-
antagonist, hypertension, diastolic function, left ventricular hypertrophy, randomised controlled trial.
INTRODUCTION
In hypertensive patients, left ventricular hypertrophy is an
important cardiovascular risk factor and there is growing
evidence that regression of left ventricular mass is an
important goal of treatment [1–4]. A recent meta-analysis
[5] did not find any significant difference between
angiotensin converting enzyme (ACE) inhibitor and
calcium blocker, but in a multicentre study in hyperten-
sive men Gottdiener et al. [6] found the best effect in the
left ventricular was with ACE inhibitor and diuretics and
that results with the calcium channel blocker diltiazem
were disappointing. These results have to be interpreted
with caution: the majority of the studies included in this
meta-analysis were open, uncontrolled, single-drug stu-
dies, and they also differed in methodology with respect
to selection of patients, duration of follow-up, treatment
schedule, and echocardiographic methodology [7, 8].
Some of the interpretation problems can be avoided if
only prospective, double-blind, randomized controlled
trials, with a parallel group design are taken into account
[7]. Only a few studies of this type compare ACE
inhibitors and calcium antagonists [6, 8–10], and some of
them cannot be considered trials for definite conclusions
about inter-agent differences because of methodological
limitations [11].
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Besides measurement of left ventricular mass, Doppler
echocardiography is often used to measure diastolic
filling abnormalities non-invasively in assessing diastolic
dysfunction. This is a common abnormality in mild to
early hypertension. Diastolic dysfunction is frequently
seen in the presence of left ventricular hypertrophy, but
this may also occur independently of the hypertrophic
process [12]. Long-term treatment of hypertension has
been shown to improve diastolic function, even in the
absence of left ventricular hypertrophy. In general, the
data suggest a beneficial effect of calcium antagonists and
ACE inhibitors, but not of beta-blockers or diuretics [12].
The primary objective of this 1-year prospective,
double-blind, randomized, parallel group, comparative
study was to compare the effects of two long-acting
antihypertensive agents, the calcium-antagonist amlodi-
pine and the ACE inhibitor lisinopril, on left ventricular
mass and diastolic filling in patients with mild to
moderate diastolic hypertension. Secondary objectives
were comparison of antihypertensive efficacy, safety and
tolerability of both drugs.
METHODS
Patient selection
Untreated, newly diagnosed patients with diastolic
hypertension were recruited from a population survey.
Blood pressure was measured in the sitting position after
5 min of rest using the right arm. Systolic (SBP) and
diastolic (DBP) blood pressure were recorded at Korotk-
off phases I and V at the nearest 2 mmHg. If a difference
in blood pressure was found between both arms (>5/
10 mmHg for DBP and SBP, respectively), the one with
the highest blood pressure was used for further measure-
ment. Both male and female patients with diastolic
hypertension (DBP 95 mmHg on three different occa-
sions, e.g. twice on the first occasion and once on the
second and third occasions; the blood pressures were
assessed within a period of 4 weeks and average
DBP< 115 mmHg during a period), between 25 and 75
years of age, from the primary healthcare system were
included in the study and received placebo treatment
during 4 weeks. Exclusion criteria were: DBP not stable
after placebo-treatment period (difference with DBP
before placebo treatment >10 mmHg), secondary or
malignant hypertension, angina pectoris, haemodynami-
cally significant valvular cardiac disease, insulin and non-
insulin dependent diabetes mellitus, and women of child-
bearing potential. All patients gave theirwritten informed
consent and the protocol was approved by the Medical
Ethics Committee of the University Hospital Groningen.
Double-blind treatment phase
After the placebo treatment period of 4 weeks (during
which the patients were seen twice, 0 and at 4 weeks), and
if DBP was stable, patients were randomized to double-
blind treatment with amlodipine 5 mg or lisinopril 10 mg.
Patients who did not meet the therapeutic response
(reduction in the average sitting DBP to a value of
90 mmHg or a fall from baseline of at least 10 mmHg to
a value of 100 mmHg) after 4 weeks of active treatment
were adjusted to the double dose. After 6 weeks of
treatment the dose remained unchanged. Patients who did
not meet the therapeutic response after 12 weeks were
excluded. Compliance of treatment was followed by
counting returned tablets at various visits.
Office and ambulatory blood pressure measurements
Office blood pressure (OBP) was measured in the sitting
position twice every visit (4, 6, 12, 26 and 52 weeks after
start of active treatment) at a 2-minute interval. The mean
of two measurements was used. Ambulatory blood
pressure (ABP) was measured at baseline and after 1
year of treatment using the SpaceLabs 90207 equipment
(SpaceLabs Inc. Redmond, Washington, USA). The non-
dominant arm was used, but if a difference in OBP
between either arm was found, the one with the highest
blood pressure was used. ABP was recorded every 30 min
during daytime (7.00–22.59 h) and at every 60 min
(because it has been shown that daytime ambulatory
blood pressure has more prognostic value) during night-
time (23.00–6.59 h), the study being in primary health-
care. Ambulatory measurements started 30–60 min before
medication intake. Patients should not have missed any
scheduled dosage within the 24 h prior to blood pressure
measurements. ABP data were analysed without data-
editing using time-weighted blood pressures for 24-h;
daytime and night-time were calculated [14].
Echocardiography
All echocardiographic examinations at baseline and after
1 year of treatment were performed by the same observer,
who was unaware of the identity of patients or BP
measurement. An Acuson XP 128 echocardiograph
(Acuson Corp., USA) was used with a 2.0 or 2.5 MHz
transducer. Mean values of three recordings were used.
Left ventricular dimensions were measured in two-
dimensional mode in accordance with the Penn conven-
tion in the left lateral decubitus position in the third or
fourth intercostal space. Measurements of end diastolic
left ventricular posterior wall (LVPW), interventricular
septum (IVS) and left ventricular end diastolic diameter
(LVEDD) were made. To estimate the left ventricular
mass (LVM) the formula of Devereux [15] was used:
LVM (g) = 1.04 {(LVPW IVS LVEDD)3-
(LVEDD)3}ÿ 13.6. LVM was divided by body surface
area (in metres squared) to calculate LVM index (LVMI).
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Left ventricular hypertrophy was defined as: LVMI
108 g/m2 for women and 118 g/m2 for men [16].
Diastolic filling abnormalities were measured with
pulsed Doppler echocardiography. Measurements were
made in the standard apical four-chamber view with the
patient in the left decubitus position. The Doppler
sampling volume was placed between the tips of the
mitral valve leaflets to obtain maximal filling velocities.
Three recordings were made, end-expiratory. Measure-
ments were performed with the Acuson calculation
software package. Early and atrial peak filling velocities
(E-peak and A-peak) were measured and their ratio (E/A
ratio) was calculated. Time measurements of the early
filling phase were performed: early acceleration time
(EAT), early deceleration time (EDT) and pressure half
time (PHT). Isovolumetric relaxation time (IVRT) was
measured as time between the end of aortic outflow signal
and beginning of mitral inflow signal in a standard five-
chamber view.
To study the tolerance of study drugs, the patients were
given a questionnaire and any other untoward event that
they reported was recorded.
Statistical analysis
Monitoring and statistical analysis (the SAS software
package) of the study was performed by an independent
monitoring agency (IMRO BV, The Netherlands).
Primary endpoints were LVMI and E/A ratio. All other
parameters were considered to be secondary. Results are
expressed as mean standard deviation (SD). A two-
tailed p< 0.05 was considered statistically significant. To
test for changes within and differences between treatment
groups, an analysis of variance (ANOVA) was carried out
with the changes in endpoints as dependent variables, and
treatment group and sex as fixed factors. Sex was dropped
from the model if it was not significant and the statistical
test then reduced to a t-test. Additionally, an analysis of
covariance (ANCOVA) was carried out with correction
for the baseline values of the primary and secondary
endpoints (continuous covariate). If there was a signifi-
cant relation with the baseline value it was also tested
whether the relation with baseline was equal (equality of
slopes) for both treatment groups. An intention-to-treat
analysis (including all randomized patients) was per-
formed. Only in the case of a large number of protocol
violators (>10%), was a per protocol analysis performed
(including all patients who completed the protocol).
To study the relation between changes in office and
ambulatory blood pressure and changes in LVMI and E/A
ratio, an ANCOVA was carried out. Estimates (with 95%
confidence interval) of the effect of change in blood
pressure on the change in LVMI and E/A ratio were
calculated. The changes in systolic and diastolic values of
the office and ambulatory blood pressure were included
separately because of the large correlation between these
blood pressures. The increase in fit of the model after
inclusion of the blood pressure was used as a measure of
correlation. To study the relation between change in
LVMI and change in E/A ratio, a Pearson correlation
coefficient was calculated.
RESULTS
Patient’s characteristics of both treatment groups are
given in Table I. There was a difference in the distribution
of sex, however, and slightly higher body mass index in
the lisinopril group might be a consequence of this
finding.
In the amlodipine and lisinopril groups, 16 of 35 (46%)
and 15 of 36 (42%) patients, respectively, were adjusted
to the higher dose of 10 and 20 mg. After 1 year, office
blood pressures were available for 69 (97%) patients,
ambulatory blood pressures for 59 (83%) patients, and
echocardiographic measurements of LVMI and E/A ratio
were available for 57 (80%) and 59 (83%), respectively.
Of the total of 59 who completed the study, 28 were in the
amlodipine group (80%) and 31 in the lisinopril group
(86%). Reasons for not completing the study in the
amlodipine group (n = 7) were: ankle oedema (1),
exanthema (1), pustulae (1), withdrawal of informed
consent (3) and no therapeutic response after 12 weeks of
treatment (1). Reasons for not completing the study in the
lisinopril group (n = 5) were: hyperkalaemia (1), dys-
Table I. Baseline characteristics of the 71 randomized patients
Amlodipine (n = 35) Lisinopril (n = 36)
Age (years) 53 10 54 11
Sex (% male) 51 72
Body mass index (kg/m2) 27.2 4.3 27.8 3.4
Office SBP/DBP (mmHg) 158 16/102 5 161 15/100 4
Heart rate (bpm) 81 12 82 11
SBP/DBP = systolic/diastolic blood pressure, values are mean standard deviation.
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pnoea (1), angina pectoris (2) and withdrawal of informed
consent (1). All the patients were included in the
intention-to-treat analysis.
Office and ambulatory blood pressure response
The office and ambulatory blood pressures at baseline and
the changes after 1 year of treatment are given in Table II.
Systolic and diastolic office blood pressures and heart rate
decreased significantly in both treatment groups. For
diastolic blood pressure there was a significant interaction
between treatment group and sex (p = 0.02). For females,
there was a difference in the change in diastolic blood
pressure between amlodipine and lisinopril in favour of
amlodipine. No differences existed between amlodipine
and lisinopril in the change in office systolic blood
pressure and heart rate. The changes in ambulatory-
derived blood pressures, during daytime, night-time and
24-h, were not significantly different between treatment
groups.
Echocardiographic measurements
The baseline values of, and the changes in, the left
ventricular dimensions and left ventricular mass estimates
are given in Table III. The percentages of patients with
left ventricular hypertrophy in the amlodipine and
lisinopril group was 14% and 9%, respectively. There
was a statistically significant decrease in LVMI in both
treatment groups: ÿ11.0 g/m2 (95% CI: ÿ6.0, ÿ16.1) in
the amlodipine group and ÿ12.6 g/m2 (95% CI: ÿ8.2,
ÿ17.0) in the lisinopril group. Septal and posterior wall
thickness decreased significantly, whereas end-diastolic
diameter increased significantly in both treatment groups.
Table II. Baseline values and changes after 1 year of treatment for office and ambulatory (ABP) blood pressure
Amlodipine Lisinopril
Baseline Change 1 year (CI) Baseline Change 1 year (CI)
Office BP SBP 157.7 16.3 ÿ14.9 (ÿ9.4,ÿ20.4)* 161.3 14.6 ÿ15.6 (ÿ10.8,ÿ20.4)*
DBP 102.0 5.2 ÿ12.4 (ÿ9.7,ÿ15.1)* 100.1 3.5 ÿ9.2 (ÿ7.0,ÿ11.5)*
HR 81.0 12.2 ÿ9.7 (ÿ5.9,ÿ13.5)* 82.4 11.1 ÿ9.5 (ÿ4.6,ÿ14.5)*
24h-ABP SBP 140.8 14.3 ÿ15.3 (ÿ10.2,ÿ20.3)* 137.5 11.1 ÿ15.0 (ÿ11.0,ÿ19.0)*
DBP 90.1 10.7 ÿ9.8 (ÿ6.4,ÿ13.2)* 87.2 8.1 ÿ9.9 (ÿ7.3,ÿ12.5)*
HR 76.3 7.8 ÿ2.4 (0.1,ÿ4.9) 75.6 7.2 ÿ2.0 (ÿ4.3,0.3)
Day-ABP SBP 145.7 13.3 ÿ15.2 (ÿ10.5,ÿ20.0)* 144.1 11.5 ÿ15.7 (ÿ11.0,ÿ20.4)*
DBP 95.1 10.4 ÿ10.2 (ÿ6.9,ÿ13.4)* 92.8 8.6 ÿ10.7 (ÿ7.7,ÿ13.7)*
HR 80.9 8.7 ÿ2.2 (1.0,ÿ5.3) 79.9 8.4 ÿ2.0 (0.9,ÿ4.9)
Night-ABP SBP 130.5 19.4 ÿ15.3 (ÿ8.7,ÿ22.0)* 124.1 14.3 ÿ13.0 (ÿ8.8,ÿ17.1)*
DBP 79.9 13.0 ÿ9.0 (ÿ4.4,ÿ13.7)* 75.7 9.9 ÿ8.3 (ÿ5.3,ÿ11.3)*
HR 67.0 7.3 ÿ3.0 (ÿ0.8,ÿ5.1)* 67.0 6.9 ÿ1.0 (ÿ3.2,1.2)
ABP = ambulatory blood pressure (in mmHg), SBP = systolic blood pressure (in mmHg), DBP = diastolic blood pressure
(in mmHg), HR = heart rate (in bpm), CI = 95% confidence interval, * = statistically significant change with respect to baseline
(p< 0.05). No differences between treatment groups except for office DBP (see text), values are mean standard deviation.
Table III. Left ventricular mass and dimensions, and weight at baseline and absolute change after 1 year of treatment for
each treatment group
Amlodipine Lisinopril
Baseline Change 1 year (CI) Baseline Change 1 year (CI)
LVMI (g/m2) 87.5 21.1 ÿ11.0 (ÿ6.0,ÿ16.1)* 90.6 16.2 ÿ12.6 (ÿ8.2,ÿ17.0)*
IVS (mm) 9.6 1.2 ÿ1.4 (ÿ1.0,ÿ1.7)* 10.0 1.1 ÿ1.2 (ÿ0.8,ÿ1.5)*
LVPW (mm) 9.5 1.2 ÿ1.2 (ÿ0.9,ÿ1.6)* 9.9 1.0 ÿ1.3 (ÿ1.0,ÿ1.7)*
LVEDD (mm) 44.9 4.8 2.5 (1.5,3.4)* 45.3 4.2 1.2 (0.5,1.9)*
LVM (g) 168.2 44.5 ÿ20.4 (ÿ10.7,ÿ30.0)* 179.0 36.8 ÿ24.6 (ÿ15.9,ÿ33.2)*
Weight (kg) 79.6 11.5 0.9 (0.0,1.7)* 83.2 12.0 0.6 (ÿ0.0,1.3)
LVM(I) = left ventricular mass (index), IVS = interventricular septum, LVPW = left ventricular posterior wall, LVEDD = left
ventricular end diastolic diameter. CI = 95% confidence interval, * = statistically significant change with respect to baseline
(p< 0.05). No differences between treatment groups. Values are mean standard deviation.
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No statistically significant differences were found be-
tween the groups. The percentage of patients with left
ventricular hypertrophy after treatment was zero in both
treatment groups. The changes in LVMI, IVS, LVPW and
LVEDD were significantly related to the baseline value of
these parameters (p = 0.0001): the higher the baseline
value, the more the decrease after treatment. These
relations were similar for both treatment groups
(p = 0.83–0.91) and there was no difference in weight
between either group.
Diastolic filling parameters at baseline and their
changes after 1 year of treatment are given in Table IV.
E/A ratios before treatment in the amlodipine and
lisinopril groups were 1.04 and 0.95, respectively. No
change in E-peak, A-peak or their ratio (E/A ratio) was
seen in either treatment group. Early deceleration time
(EDT) and pressure half time (PHT) decreased in both
treatment groups. In the lisinopril group a significant
decrease in isovolumetric relaxation time (IVRT) was
seen as well. Heart rate (HR) decreased significantly in
the amlodipine group. Early acceleration time (EAT)
remained unchanged for both treatment groups. No
statistically significant differences between either treat-
ment group were found. There was no significant relation
between the baseline value of the E/A ratio and the
change in E/A ratio after treatment (p = 0.65). Changes in
all secondary parameters (except for A-peak: p = 0.45)
were significantly related to their baseline value
(p = 0.0001): the more disturbance in these parameters
before treatment, the more improvement after interven-
tion. For the PHT, this relation was significantly stronger
for patients treated with amlodipine in comparison with
patients treated with lisinopril: p = 0.049.
Relations between changes in blood pressure, LVMI
and E/A ratio
Results of an analysis of covariance assessing the
Table IV. Left ventricular filling parameters at baseline and absolute change after 1 year of treatment for each treatment
group
Amlodipine Lisinopril
Baseline Change 1 year (CI) Baseline Change 1 year (CI)
E-peak (m/s) 0.76 0.12 0.02 (ÿ0.03,0.07) 0.70 0.12 0.01 (ÿ0.02,0.05)
A-peak (m/s) 0.75 0.13 ÿ0.02 (ÿ0.04,0.01) 0.76 0.13 0.01 (ÿ0.02,0.04)
E/A-ratio 1.04 0.24 0.07 (ÿ0.01,0.15) 0.95 0.27 0.01 (ÿ0.06,0.08)
EAT (ms) 98.1 13.2 2.0 (ÿ3.9,7.9) 102.1 14.4 3.0 (ÿ2.0,8.0)
EDT (ms) 208.5 29.4 ÿ24.5 (ÿ36.7,ÿ12.4)* 215.1 36.6 ÿ22.6 (ÿ34.0,ÿ11.0)*
PHT (m/s) 61.3 8.5 ÿ7.3 (ÿ10.8,ÿ3.7)* 63.1 10.7 ÿ6.7 (ÿ10.0,ÿ3.5)*
IVRT (ms) 106.0 17.0 ÿ3.0 (ÿ8.3,2.4) 108.5 13.3 ÿ6.5 (ÿ11.8,ÿ1.2)*
HR (bpm) 68.6 9.2 ÿ3.8 (ÿ6.8,ÿ0.7)* 68.7 8.2 ÿ1.0 (ÿ4.4,2.4)
E-peak, A-peak and E/A-ratio = early and atrial peak filling velocity and their ratio, EAT = early acceleration time, EDT = early
deceleration time, PHT = pressure half time, IVRT = isovolumetricular relaxation time, HR = heart rate. CI = 95% confidence interval,
* = statistically significant change with respect to baseline (p< 0.05). No differences between treatment groups. Values are
mean standard deviation.
Table V. Relations between changes in LVMI and E/A ratio, and changes in office and ambulatory blood pressures
Estimate (CI) DR2
LVMI Office SBP 0.17 (ÿ0.04,0.38) 0.046
Office DBP 0.48 (0.02,0.94) 0.076
24 h SBP 0.43 (0.18,0.68) 0.178
24 h DBP 0.67 (0.29,1.05) 0.192
E/A ratio Office SBP ÿ0.0033 (ÿ0.0066,0.0000) 0.063
Office DBP ÿ0.0125 (ÿ0.0193,ÿ0.0057) 0.182
24 h SBP ÿ0.0075 (ÿ0.0109,ÿ0.0041) 0.228
24 h DBP ÿ0.0112 (ÿ0.0164,ÿ0.0060) 0.225
LVMI = left ventricular mass index, E/A ratio = early to atrial peak filling velocity ratio, SBP = systolic blood pressure,
DBP = diastolic blood pressure. Estimate: estimate of the effect of change in blood pressure (mmHg) on change in LVMI (g/m2) and
E/A ratio (e.g. 1 mmHg rise in 24 h DBP is related to a change in LVMI of 0.67 g/m2); DR2: increase in fit of the model after including
the blood pressure separately, CI = 95% confidence interval.
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relationships between the changes in office and ambula-
tory blood pressures and the changes in primary endpoints
are given in Table V. A decrease in 24-h ambulatory
blood pressures is related to a decrease in LVMI. The
change in the fit of the model after the change in blood
pressure was added is given by DR2. However, the
differences were not statistically significant. There was no
significant relation between changes in LVMI and E/A
ratio (r =ÿ0.15; p = 0.26).
Adverse events
Adverse events related to the therapy occurred in 6
patients (17%) of the amlodipine group and in 7 (19%) of
the lisinopril group. The most frequently observed
adverse events were peripheral oedema in five patients
(14%) of the amlodipine group and dizziness in four
patients (11%) of the lisinopril group. The overall
incidence of adverse events was considerably higher
when adverse events of unknown relationship were
added: 69% in the amlodipine group and 58% in the
lisinopril group. There was no evidence of a difference
between the two treatment groups with respect to the
number of patients with adverse events.
DISCUSSION
This study shows that the effects of amlodipine and
lisinopril on left ventricular mass and diastolic filling after
1 year of treatment in patients with previously untreated
mild to moderate hypertension are similar. Left ventri-
cular mass index in both treatment groups decreased
significantly after 1 year of treatment: ÿ11.0 g/m2 and
ÿ12.6 g/m2 in the amlodipine and lisinopril groups,
respectively. No significant changes in E/A ratio were
seen.
In females, amlodipine decreased office diastolic blood
pressure better than lisinopril, but ambulatory blood
pressure data showed equal changes in diastolic blood
pressures for amlodipine and lisinopril. Because the
reproducibility of ambulatory blood pressure is superior
Table VI. Published randomized controlled trials (without non-pharmacological intervention, classified by type of
blinding), with a parallel group design, comparing ACE inhibitors and calcium antagonists in mild to moderate essential
hypertension (DBP 95 mmHg)
Study
Agent




(weeks) Monotherapy DLVMI DE/A
Randomized, parallel group comparative studies: double-blind
[8] ## Nifedipine SR (40–80) 20 24 no, HCT added ÿ16%*** –
–
Perindopril (4–8) 20 ÿ14%***
[9] ! Nifedipine (40) 15 24 no, HCT added ÿ9%*** –
–
Fosinopril (20) 16 ÿ15%***
[10] ! Isradipine (5) 13 12 yes ÿ12%** 2%
Enalapril (20) 13 ÿ4% 10%
Present Amlodipine (5–10) 35 52 yes ÿ13%*** 7%
study $,## Lisinopril (10–20) 36 ÿ14%*** 1%










































DLVMI = change in left ventricular mass index; DE/A = change in E/A ratio, HCT = hydrochlorothiazide. * p< 0.05, ** p< 0.01,
*** p< 0.001, # p< 0.001 within study population, ## statistically significant relation between change in blood pressure and change
in LVMI, @ analysed patients, $ previously untreated patients, & patients selected on DBP and SBP. ! Statistically significant
difference in DLVMI between treatment groups.
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to that of the office blood pressure, the blood pressure
decrease in both treatment groups was considered to be
equal [17].
Comparison with other studies
The results of eight published randomized controlled
trials concerning the effects on LVMI and comparing
ACE inhibitors and calcium antagonists are given in
Table VI. According to recently designed criteria for trials
on regression of left ventricular hypertrophy, none of
these eight published studies can be considered a trial for
definite conclusions about inter-agent differences [11].
All studies were randomized, between-agent compari-
sons, in women and men, and used echocardiography to
assess regression of left ventricular hypertrophy (selec-
tion criteria used). However, only three [8–10] were
double-blind, only one [18] had a sufficient follow-up (1
year), and five of eight studies [8, 18–21] analysed
relations between changes in blood pressure and changes
in LVMI. The present study fulfilled all the criteria
mentioned above and, in addition, was the only study
which included previously untreated patients. There are
no studies, including the present, which fulfilled the last
two criteria: including an ethnically diverse population
and at least 150–200 patients per treatment arm. To
exclude the possibility of inter-agent differences, it is
indeed important to include larger numbers of patients.
The relatively large 95% confidence intervals of the
differences in LVMI in both treatment groups found in the
present study also point at a non-optimal precision. Even
Dahlo¨f et al. [22], in their meta analysis comprising over
2000 patients also ran into some problems, e.g. only 17%
of the studies were randomized, follow-up was on average
10 months and number of patients per study was average
21, etc. More accurate estimates of the effects can be
obtained from meta-analyses of well-designed parallel
group comparative studies. The compiled data of the
studies summarized in Table VI suggest that there are no
differences between calcium antagonists and ACE
inhibitors with respect to regression of LVMI. Devereux
and Dahlo¨f [11] have suggested the following types of
studies for the future for establishing the therapeutic
usefulness of treating LVH per se and not just for
lowering the blood pressure: (1) Medium-sized studies
with 300–400 patients followed up for at least 6 months to
determine definitively whether inter-agent differences in
reduction of LV mass exist, and (2) large, long-term trials
with at least 1200 patients followed up for a minimum of
4 years to determine whether LVH reversal improves
prognosis over and above blood pressure reduction and
the type of treatment used.
In only two [8, 19] of the eight studies summarized in
Table VI, a significant relation between changes in blood
pressure and changes in LVMI could be found. In the
present study, the changes in LVMI were significantly
related to the changes in blood pressure and this relation
proved to be stronger for ambulatory blood pressure than
for office blood pressures. If regression of LVMI is
considered to be a good predictor of prognosis, these
results suggest that prognosis is more strongly related to
changes in ambulatory blood pressures.
Diastolic filling
Regression of left ventricular mass is usually associated
with improvement of diastolic filling. In this study, E/A
ratio did not change significantly; changes in E/A ratio
were not related to the pretreatment level, and there was a
very weak relation between changes in LVMI and
changes in E/A ratio. These results may be explained by
the fact that in neither of the treatment groups was E/A
ratio markedly abnormal before the start of treatment. It
can be seen from Table VI that statistically significant
changes in E/A ratio were seen in only two of six studies
[18, 20].
The lack of hypertrophy at baseline in the majority of
our patient population is comparable to that in the
TOMHS study [24], J. D. Neaton et al.’s work [25] and
the latest issue of Circulation (1997) [6]. We would like to
point out that prevalence of hypertrophy in mild to
moderate hypertension in these primary care patients is
very low.
In this study, no differences were found in the changes
in isovolumetric relaxation time (IVRT) (decreased
significantly during lisinopril treatment but not in
response to amlodipine), peak early filling (E-peak) and
early acceleration time (EAT) within the groups. How-
ever, the changes in IVRT, E-peak and EAT were
significantly related to their baseline values, which means
that improvement can be seen after treatment with both
agents at higher levels of dysfunction. Deceleration of the
early filling velocity is strongly related to left ventricular
compliance [22]. In both treatment groups, significant and
similar changes in early deceleration time (EDT) and
pressure half time (PHT) were seen, whereas peak early
filling (E-peak) remained unchanged. Furthermore,
changes in EDT and PHT were significantly related to
the baseline values. Thus, although the E/A ratio
remained unchanged, the analysis of these secondary
parameters shows that both amlodipine and lisinopril alter
diastolic filling and that improvement of diastolic filling is
dependent on the level of impairment before treatment.
As far as the mechanism of regression of LVH is
concerned, in the experimental studies it has been shown
that pharmacologic agents that interfere with the
adrenergic nervous system may induce regression in
myocardial mass due to reduction in myocyte size, but
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with unchanged or even increased myocardial collagen
concentration [26]. Treatment of spontaneously hyper-
tensive rats with the ACE inhibitor lisinopril resulted in a
complete normalization of this remodelling, including
coronary flow reserve [27]. Similar findings have been
observed with captopril [28] and the calcium antagonist
nifedipine [29].
Thus, based upon experimental experience, adrenergic
blocking drugs seem to induce regression of LVH mainly
by reducing myocyte hypertrophy, whereas calcium
antagonists and ACE inhibitors may have favourable
effects on structural myocardial and coronary artery
remodelling as well.
The higher incidence of adverse events reported in our
study and withdrawal from the study are not uncommon,
particularly when a questionnaire recording adverse
events is used.
CONCLUSION
The effects of amlodipine and lisinopril on left ventricular
mass and E/A ratio after 1 year of treatment in patients
with previously untreated mild to moderate hypertension
are similar. Left ventricular mass index in both treatment
groups decreased significantly whereas the E/A ratio did
not change. The compiled results of the present study and
those of other published clinical trials suggest that there
are no differences between calcium antagonists and ACE
inhibitors with respect to regression of LVMI. But larger,
controlled studies, as also suggested by Otterstad et al.
[30], of various treatment regimens are still needed to
demonstrate inter-drug differences and to establish
whether drug-induced regression can improve the prog-
nosis of hypertensive LVH independently or with the
antihypertensive effect.
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